Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43936   clinical trials with a EudraCT protocol, of which   7310   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA ® ) and CNTO 1959 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy

    Summary
    EudraCT number
    2011-001122-18
    Trial protocol
    HU   CZ   BG  
    Global end of trial date
    05 May 2014

    Results information
    Results version number
    v2(current)
    This version publication date
    15 Jul 2016
    First version publication date
    31 Jul 2015
    Other versions
    v1
    Version creation reason
    • Correction of full data set
    Review of data

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CNTO1275ARA2001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01645280
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Janssen-Cilag International NV
    Sponsor organisation address
    Turnhoutseweg 30, 2340, Beerse, Belgium,
    Public contact
    Clinical Registry Group, Janssen-Cilag International NV, ClinicalTrialsEU@its.jnj.com
    Scientific contact
    Clinical Registry Group, Janssen-Cilag International NV, ClinicalTrialsEU@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    05 May 2014
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    05 May 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing signs and symptoms of disease in subjects with active Rheumatoid Arthritis [RA] despite concomitant methotrexate (MTX) therapy, and to evaluate the safety of ustekinumab and CNTO 1959 in this population.
    Protection of trial subjects
    This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Known instances of nonconformance were documented and are not considered to have had an impact on the overall conclusions of this study. The study protocol and amendment were reviewed by an Independent Ethics Committee (IEC) or Institutional Review Board (IRB). Safety assessments included monitoring and recording all adverse effects [AE] and serious adverse effects [SAE], laboratory evaluations (hematology, blood chemistry, urinalysis and immunogenicity), vital signs, body weight, electro cardio gram [ECG] and injection site reactions through Week 48.
    Background therapy
    Stable dose of Methotrexate
    Evidence for comparator
    -
    Actual start date of recruitment
    02 Jul 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 23
    Country: Number of subjects enrolled
    Bulgaria: 9
    Country: Number of subjects enrolled
    Chile: 6
    Country: Number of subjects enrolled
    Colombia: 43
    Country: Number of subjects enrolled
    Czech Republic: 1
    Country: Number of subjects enrolled
    Hungary: 20
    Country: Number of subjects enrolled
    Poland: 35
    Country: Number of subjects enrolled
    Russian Federation: 86
    Country: Number of subjects enrolled
    Singapore: 4
    Country: Number of subjects enrolled
    Ukraine: 46
    Country: Number of subjects enrolled
    United States: 1
    Worldwide total number of subjects
    274
    EEA total number of subjects
    65
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    235
    From 65 to 84 years
    39
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 501 subjects were screened of which 274 subjects were randomized, and 273 participants were treated.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo + Methotrexate (MTX)
    Arm description
    Placebo at Weeks 0, 4, 12, 16, 20, 28 unless early escape at Week 16. Subjects who early escape at Week 16 received ustekinumab 90 mg at Weeks 16, 20, and 28.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo injection at Weeks 0, 4, 12, 16, 20, 28 unless early escape at Week 16. Subjects who early escape at Week 16 received ustekinumab 90 mg at Weeks 16, 20, and 28.

    Arm title
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate
    Arm description
    Participants randomized to receive Ustekinumab 90 milligram (mg) subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).
    Arm type
    Experimental

    Investigational medicinal product name
    Ustekinumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Ustekinumab 90 mg injected subcutaneously at Weeks 0, 4, 12, 20, and 28. Placebo injection at Week 16 to keep the blind.

    Arm title
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate
    Arm description
    Participants randomized to receive Ustekinumab 90 milligram (mg) subcutaneously at Week 0, 4 and then every 12 weeks (Week 16 and 28).
    Arm type
    Experimental

    Investigational medicinal product name
    Ustekinumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Ustekinumab 90 mg injected subcutaneously at Weeks 0, 4, 16, and 28. Placebo injection at weeks 12 and 20 to keep the blind.

    Arm title
    CNTO1959 50 mg Every 8 Weeks + Methotrexate
    Arm description
    Participants randomized to receive CNTO1959 50 mg subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).
    Arm type
    Experimental

    Investigational medicinal product name
    CNTO 1959
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    CNTO1959 50 mg injected subcutaneously at Weeks 0, 4, 12, 20, and 28. Placebo injection at Week 16 to keep the blind.

    Arm title
    CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Arm description
    Participants randomized to receive CNTO1959 200 mg subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).
    Arm type
    Experimental

    Investigational medicinal product name
    CNTO 1959
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    CNTO 1959 200 mg injected subcutaneously at Weeks 0, 4, 12, 20 and 28. Placebo injection at Week 16 to keep the blind.

    Number of subjects in period 1
    Placebo + Methotrexate (MTX) Ustekinumab 90 mg Every 8 Weeks + Methotrexate Ustekinumab 90 mg Every 12 Weeks + Methotrexate CNTO1959 50 mg Every 8 Weeks + Methotrexate CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Started
    55
    55
    55
    55
    54
    Completed
    50
    51
    50
    51
    50
    Not completed
    5
    4
    5
    4
    4
         Consent withdrawn by subject
    -
    -
    1
    1
    -
         Adverse event, non-fatal
    2
    1
    3
    2
    -
         Death
    -
    1
    -
    -
    -
         Unspecified
    1
    -
    -
    -
    -
         Lack of efficacy
    2
    2
    1
    1
    4

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo + Methotrexate (MTX)
    Reporting group description
    Placebo at Weeks 0, 4, 12, 16, 20, 28 unless early escape at Week 16. Subjects who early escape at Week 16 received ustekinumab 90 mg at Weeks 16, 20, and 28.

    Reporting group title
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive Ustekinumab 90 milligram (mg) subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group title
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive Ustekinumab 90 milligram (mg) subcutaneously at Week 0, 4 and then every 12 weeks (Week 16 and 28).

    Reporting group title
    CNTO1959 50 mg Every 8 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive CNTO1959 50 mg subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group title
    CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive CNTO1959 200 mg subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group values
    Placebo + Methotrexate (MTX) Ustekinumab 90 mg Every 8 Weeks + Methotrexate Ustekinumab 90 mg Every 12 Weeks + Methotrexate CNTO1959 50 mg Every 8 Weeks + Methotrexate CNTO1959 200 mg Every 8 Weeks + Methotrexate Total
    Number of subjects
    55 55 55 55 54 274
    Title for AgeCategorical
    Units: subjects
        Children (2-11 years)
    0 0 0 0 0 0
        Adolescents (12-17 years)
    0 0 0 0 0 0
        Adults (18-64 years)
    51 47 44 50 43 235
        From 65 to 84 years
    4 8 11 5 11 39
        85 years and over
    0 0 0 0 0 0
    Title for AgeContinuous
    Units: years
        arithmetic mean (standard deviation)
    51.1 ± 10.57 50.8 ± 13.01 51.4 ± 13.59 49.9 ± 12.85 54.6 ± 11.34 -
    Title for Gender
    Units: subjects
        Female
    48 46 47 45 42 228
        Male
    7 9 8 10 12 46

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo + Methotrexate (MTX)
    Reporting group description
    Placebo at Weeks 0, 4, 12, 16, 20, 28 unless early escape at Week 16. Subjects who early escape at Week 16 received ustekinumab 90 mg at Weeks 16, 20, and 28.

    Reporting group title
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive Ustekinumab 90 milligram (mg) subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group title
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive Ustekinumab 90 milligram (mg) subcutaneously at Week 0, 4 and then every 12 weeks (Week 16 and 28).

    Reporting group title
    CNTO1959 50 mg Every 8 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive CNTO1959 50 mg subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group title
    CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Reporting group description
    Participants randomized to receive CNTO1959 200 mg subcutaneously at Week 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Subject analysis set title
    Intent-to-treat (ITT)
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    The intent-to-treat (ITT) population included all randomized participants. For early escape, subjects were considered as non-responders for subsequent visits through Week 28.

    Primary: Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28

    Close Top of page
    End point title
    Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28
    End point description
    The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) patient's assessment of arthritis pain-visual analog scale, 2) patient's global assessment of disease activity-visual analog scale, 3) physician's global assessment of disease activity-visual analog scale, 4) patient’s assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-Di), 5) C-reactive protein (CRP).
    End point type
    Primary
    End point timeframe
    Week 28
    End point values
    Placebo + Methotrexate (MTX) Ustekinumab 90 mg Every 8 Weeks + Methotrexate Ustekinumab 90 mg Every 12 Weeks + Methotrexate CNTO1959 50 mg Every 8 Weeks + Methotrexate CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Number of subjects analysed
    55
    55
    55
    55
    54
    Units: percentage of participants
        number (not applicable)
    40
    52.7
    54.5
    38.2
    44.4
    Statistical analysis title
    Statistical analysis 1
    Comparison groups
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.184
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Statistical analysis title
    Statistical analysis 2
    Comparison groups
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.13
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Statistical analysis title
    Statistical analysis 3
    Comparison groups
    CNTO1959 200 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.642
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Statistical analysis title
    Statistical analysis 4
    Comparison groups
    CNTO1959 50 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.832
    Method
    Cochran-Mantel-Haenszel
    Confidence interval

    Secondary: Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28

    Close Top of page
    End point title
    Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28
    End point description
    The DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, CRP milligram per liter (mG/L) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 100 mm); higher scores indicated greater disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
    End point type
    Secondary
    End point timeframe
    From Baseline to Week 28
    End point values
    Placebo + Methotrexate (MTX) Ustekinumab 90 mg Every 8 Weeks + Methotrexate Ustekinumab 90 mg Every 12 Weeks + Methotrexate CNTO1959 50 mg Every 8 Weeks + Methotrexate CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Number of subjects analysed
    55
    54
    55
    55
    54
    Units: units on scale
        least squares mean (standard error)
    -0.9353 ± 0.17414
    -1.5256 ± 0.1853
    -1.4964 ± 0.18349
    -1.4164 ± 0.17329
    -1.2126 ± 0.17055
    Statistical analysis title
    Statistical analysis 1
    Comparison groups
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.019
    Method
    ANCOVA
    Confidence interval
    Statistical analysis title
    Statistical analysis 2
    Comparison groups
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.025
    Method
    ANCOVA
    Confidence interval
    Statistical analysis title
    Statistical analysis 3
    Comparison groups
    CNTO1959 200 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.248
    Method
    ANCOVA
    Confidence interval
    Statistical analysis title
    Statistical analysis 4
    Comparison groups
    CNTO1959 50 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.045
    Method
    ANCOVA
    Confidence interval

    Secondary: Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12

    Close Top of page
    End point title
    Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12
    End point description
    The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 2) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 3) Physician's Global Assessment of Disease Activity-Visual Analog Scale, 4) Patient’s Assessment of Physical Function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI), 5) C-reactive Protein (CRP).
    End point type
    Secondary
    End point timeframe
    Week 12
    End point values
    Placebo + Methotrexate (MTX) Ustekinumab 90 mg Every 8 Weeks + Methotrexate Ustekinumab 90 mg Every 12 Weeks + Methotrexate CNTO1959 50 mg Every 8 Weeks + Methotrexate CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Number of subjects analysed
    55
    54
    55
    55
    54
    Units: percentage of participants
        number (not applicable)
    29.1
    37
    34.5
    20
    33.3
    Statistical analysis title
    Statistical analysis 1
    Comparison groups
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.381
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Statistical analysis title
    Statistical analysis 2
    Comparison groups
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.543
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Statistical analysis title
    Statistical analysis 3
    Comparison groups
    CNTO1959 200 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.629
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Statistical analysis title
    Statistical analysis 4
    Comparison groups
    CNTO1959 50 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.273
    Method
    Cochran-Mantel-Haenszel
    Confidence interval

    Secondary: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28

    Close Top of page
    End point title
    Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28
    End point description
    The Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 28
    End point values
    Placebo + Methotrexate (MTX) Ustekinumab 90 mg Every 8 Weeks + Methotrexate Ustekinumab 90 mg Every 12 Weeks + Methotrexate CNTO1959 50 mg Every 8 Weeks + Methotrexate CNTO1959 200 mg Every 8 Weeks + Methotrexate
    Number of subjects analysed
    55
    54
    55
    55
    54
    Units: units on scale
        least squares mean (standard error)
    -0.2951 ± 0.07454
    -0.4805 ± 0.07205
    -0.4412 ± 0.07153
    -0.3969 ± 0.07695
    -0.4105 ± 0.07562
    Statistical analysis title
    Statistical analysis 1
    Comparison groups
    Ustekinumab 90 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.06
    Method
    ANCOVA
    Confidence interval
    Statistical analysis title
    Statistical analysis 2
    Comparison groups
    Ustekinumab 90 mg Every 12 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.134
    Method
    ANCOVA
    Confidence interval
    Statistical analysis title
    Statistical analysis 3
    Comparison groups
    CNTO1959 200 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    109
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.28
    Method
    ANCOVA
    Confidence interval
    Statistical analysis title
    Statistical analysis 4
    Comparison groups
    CNTO1959 50 mg Every 8 Weeks + Methotrexate v Placebo + Methotrexate (MTX)
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.345
    Method
    ANCOVA
    Confidence interval

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Through week 48
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.0
    Reporting groups
    Reporting group title
    Placebo+MTX
    Reporting group description
    Placebo at Weeks 0, 4, 12, 16, 20 and 28 unless early escape at Week 16.

    Reporting group title
    Placebo (Early Escape)
    Reporting group description
    Participants in placebo group who early escaped at Weeks 16 and received ustekinumab 90 milligram (mg) subcutaneously at Week 16, 20 and 28.

    Reporting group title
    Ustekinumab 90 mg Every 8 Weeks + MTX
    Reporting group description
    Participants received ustekinumab 90 milligram (mg) subcutaneously at Weeks 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group title
    Ustekinumab 90 mg Every 12 Weeks + MTX
    Reporting group description
    Participants received ustekinumab 90 milligram (mg) subcutaneously at Weeks 0, 4 and then every 12 weeks (Week 16 and 28).

    Reporting group title
    CNTO1959 50 mg Every 8 Weeks + MTX
    Reporting group description
    Participants received CNTO1959 50 mg subcutaneously at Weeks 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Reporting group title
    CNTO1959 200 mg Every 8 Weeks + MTX
    Reporting group description
    Participants received CNTO1959 200 mg subcutaneously at Weeks 0, 4 and then every 8 weeks (Week 12, 20 and 28).

    Serious adverse events
    Placebo+MTX Placebo (Early Escape) Ustekinumab 90 mg Every 8 Weeks + MTX Ustekinumab 90 mg Every 12 Weeks + MTX CNTO1959 50 mg Every 8 Weeks + MTX CNTO1959 200 mg Every 8 Weeks + MTX
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 55 (5.45%)
    1 / 16 (6.25%)
    4 / 54 (7.41%)
    3 / 55 (5.45%)
    0 / 55 (0.00%)
    3 / 54 (5.56%)
         number of deaths (all causes)
    0
    0
    1
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Breast Cancer Stage I
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    1 / 54 (1.85%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Squamous cell carcinoma of lung
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    1 / 55 (1.82%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Concussion
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    1 / 54 (1.85%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Shock
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    1 / 54 (1.85%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Angina Unstable
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Sciatica
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    1 / 54 (1.85%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transient Ischaemic Attack
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    1 / 55 (1.82%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    1 / 54 (1.85%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Ileus
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    1 / 55 (1.82%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Rheumatoid arthritis
         subjects affected / exposed
    1 / 55 (1.82%)
    1 / 16 (6.25%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lobar Pneumonia
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    1 / 54 (1.85%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    1 / 54 (1.85%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 55 (0.00%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    1 / 54 (1.85%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo+MTX Placebo (Early Escape) Ustekinumab 90 mg Every 8 Weeks + MTX Ustekinumab 90 mg Every 12 Weeks + MTX CNTO1959 50 mg Every 8 Weeks + MTX CNTO1959 200 mg Every 8 Weeks + MTX
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    18 / 55 (32.73%)
    6 / 16 (37.50%)
    20 / 54 (37.04%)
    17 / 55 (30.91%)
    14 / 55 (25.45%)
    21 / 54 (38.89%)
    Investigations
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    1 / 55 (1.82%)
    1 / 16 (6.25%)
    0 / 54 (0.00%)
    1 / 55 (1.82%)
    1 / 55 (1.82%)
    0 / 54 (0.00%)
         occurrences all number
    1
    1
    0
    1
    1
    0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    3 / 55 (5.45%)
    1 / 16 (6.25%)
    4 / 54 (7.41%)
    2 / 55 (3.64%)
    1 / 55 (1.82%)
    1 / 54 (1.85%)
         occurrences all number
    3
    1
    4
    2
    1
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 55 (5.45%)
    1 / 16 (6.25%)
    2 / 54 (3.70%)
    5 / 55 (9.09%)
    2 / 55 (3.64%)
    3 / 54 (5.56%)
         occurrences all number
    3
    1
    3
    5
    2
    3
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 16 (0.00%)
    3 / 54 (5.56%)
    0 / 55 (0.00%)
    1 / 55 (1.82%)
    3 / 54 (5.56%)
         occurrences all number
    1
    0
    3
    0
    1
    3
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 16 (6.25%)
    2 / 54 (3.70%)
    1 / 55 (1.82%)
    1 / 55 (1.82%)
    1 / 54 (1.85%)
         occurrences all number
    0
    1
    2
    1
    1
    1
    Gastrointestinal disorders
    Dyspepsia
         subjects affected / exposed
    1 / 55 (1.82%)
    1 / 16 (6.25%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Photosensitivity Reaction
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 16 (6.25%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Rheumatoid Arthritis
         subjects affected / exposed
    1 / 55 (1.82%)
    1 / 16 (6.25%)
    2 / 54 (3.70%)
    5 / 55 (9.09%)
    2 / 55 (3.64%)
    4 / 54 (7.41%)
         occurrences all number
    1
    1
    2
    7
    2
    4
    Back Pain
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 16 (0.00%)
    0 / 54 (0.00%)
    0 / 55 (0.00%)
    3 / 55 (5.45%)
    1 / 54 (1.85%)
         occurrences all number
    1
    0
    0
    0
    4
    1
    Infections and infestations
    Influenza
         subjects affected / exposed
    3 / 55 (5.45%)
    0 / 16 (0.00%)
    1 / 54 (1.85%)
    3 / 55 (5.45%)
    3 / 55 (5.45%)
    3 / 54 (5.56%)
         occurrences all number
    4
    0
    2
    3
    3
    4
    Nasopharyngitis
         subjects affected / exposed
    3 / 55 (5.45%)
    1 / 16 (6.25%)
    5 / 54 (9.26%)
    4 / 55 (7.27%)
    3 / 55 (5.45%)
    4 / 54 (7.41%)
         occurrences all number
    3
    1
    8
    6
    6
    7
    Bronchitis
         subjects affected / exposed
    1 / 55 (1.82%)
    0 / 16 (0.00%)
    2 / 54 (3.70%)
    2 / 55 (3.64%)
    2 / 55 (3.64%)
    4 / 54 (7.41%)
         occurrences all number
    1
    0
    2
    2
    2
    5
    Pharyngitis
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 16 (6.25%)
    0 / 54 (0.00%)
    1 / 55 (1.82%)
    1 / 55 (1.82%)
    0 / 54 (0.00%)
         occurrences all number
    0
    1
    0
    1
    1
    0
    Urinary Tract Infection
         subjects affected / exposed
    0 / 55 (0.00%)
    1 / 16 (6.25%)
    1 / 54 (1.85%)
    1 / 55 (1.82%)
    0 / 55 (0.00%)
    0 / 54 (0.00%)
         occurrences all number
    0
    1
    1
    1
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 Mar 2012
    The length of study was reduced to a 28-week placebo-controlled period with 20-week follow-up period. The hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) testings were added at the screening. The total blood volume was updated to include the additional laboratory testing added to the protocol. The treatment failure criteria were updated to include all reasons for discontinuation of study agent (such as due to adverse events [AEs]). A 12-lead ECG was added to the Week 28 safety evaluations. Instructions were added to the protocol to avoid unblinding by the Principal Investigator because of serious adverse events (SAEs) related to disease progression. Added that ribonucleic acid (RNA) would be measured from whole blood as well as serum in the study. The unit 10-cm was removed in reference to Visual Analogue Scale (VAS) since an electronic patient-reported outcome e-PRO) device was to be used to collect the VAS in the study. Preplanned surgery/procedure(s) row was removed from the time and events schedule since this row did not pertain to this study.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    No notable study limitations were identified by the Sponsor.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA